Second-generation glycopeptide antibiotic research.docVIP

 PAGE \* MERGEFORMAT 26 Second-generation glycopeptide antibiotic research Author: Shang Xin-Yan Juan Li-ju-jun XU Ji-Yang Dai-Jie Chen Abstract With the continuing escalation of drug-resistant bacteria, vancomycin-resistant enterococci, a high degree of resistance to glycopeptide antibiotics in the emergence of Staphylococcus aureus, giving the clinical anti-infective therapy has brought great difficulties. Development of new glycopeptide antibiotics without delay. People to vancomycin and other natural glycopeptide antibiotics, chemical modification, has been a series of valuable derivatives, in which oritavancin, dalbavancin and telavancin has entered Phase Ⅲ clinical and registration of new medicines. In this paper, the second-generation glycopeptide antibiotics structural features, pharmacodynamics and pharmacokinetic characteristics and clinical application are reviewed. Keywords: second-generation glycopeptide antibiotic Oritavancin Dalbavancin Telavancin ABSTRACT Development of resistance to antibacterial agents, especially the advent of vancomycin  resistant Enterococcus (VRE) and glycopeptide  resistant Staphylococcus aureus (GRSA) is a mounting problem that continues to compromise the clinical effectiveness of anti  infectious drugs. It is essential to develop new glycopeptide antibiotics. Three of these new derivatives obtained by semi  synthesis starting from natural compounds, are now in clinical development (oritavancin and telavancin, as derivatives of vancomycin; and dalbavancin, as a derivative of teicoplanin). The review focuses on the structures , pharmacokinetic and pharmacodynamic parameters and the clinical research status related to the second  generation glycopeptide antibiotics. KEY WORDS The second  generation glycopeptide antibiotics; Oritavancin; Dalbavancin; Telavancin Ever since penicillin was discovered and used in clinical after the lifting of antibiotics for human bacterial infec